Trial Profile
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs VXM-01 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors VAXIMM
- 17 Oct 2018 Status changed from active, no longer recruiting to completed.
- 28 Apr 2017 Planned number of patients changed from 24 to 6.
- 28 Apr 2017 Status changed from recruiting to active, no longer recruiting.